AU1537292A
(en)
*
|
1991-04-16 |
1992-11-17 |
Nippon Shinyaku Co. Ltd. |
Method of manufacturing solid dispersion
|
CA2124821C
(en)
|
1991-12-18 |
2003-10-07 |
Isaac Ghebre-Sellassie |
Novel solid pharmaceutical dispersions
|
WO1995013794A1
(fr)
*
|
1993-11-18 |
1995-05-26 |
Nippon Shinyaku Co., Ltd. |
Procede pour produire une composition de medicament stable, et preparation pharmaceutique
|
SE9502244D0
(sv)
*
|
1995-06-20 |
1995-06-20 |
Bioglan Ab |
A composition and a process for the preparation thereof
|
AUPN814496A0
(en)
*
|
1996-02-19 |
1996-03-14 |
Monash University |
Dermal penetration enhancer
|
ES2325046T3
(es)
|
1996-06-26 |
2009-08-24 |
The Board Of Regents, The University Of Texas System |
Formulacion farmaceutica extruible por fusion en caliente.
|
EP0954288B1
(en)
*
|
1996-06-28 |
2004-08-11 |
Schering Corporation |
Solid solution of an antifungal agent with enhanced bioavailability
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
US5955475A
(en)
*
|
1997-06-30 |
1999-09-21 |
Endo Pharmaceuticals Inc. |
Process for manufacturing paroxetine solid dispersions
|
HN1998000115A
(es)
*
|
1997-08-21 |
1999-06-02 |
Warner Lambert Co |
Formas de dosificación farmacéuticas sólidas
|
CA2214895C
(en)
*
|
1997-09-19 |
1999-04-20 |
Bernard Charles Sherman |
Improved pharmaceutical composition comprising fenofibrate
|
US6376542B1
(en)
*
|
1997-12-19 |
2002-04-23 |
Bissell Homecare, Inc. |
Aqueous miticide compositions containing benzyl benzoate
|
US6107341A
(en)
*
|
1997-12-19 |
2000-08-22 |
Bissell Homecare, Inc. |
Aqueous miticide containing benzyl benzoate
|
IL136460A0
(en)
*
|
1997-12-22 |
2001-06-14 |
Schering Corp |
Molecular dispersion composition with enhanced bioavailability
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
DE19913606A1
(de)
*
|
1999-03-25 |
2000-09-28 |
Basf Ag |
Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
|
DE19916383A1
(de)
*
|
1999-03-31 |
2000-10-05 |
Schering Ag |
Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
|
MXPA01012225A
(es)
*
|
1999-05-28 |
2002-08-12 |
Abbott Lab |
Formulaciones novedosas que comprenden agentes reguladores de lipido.
|
DE19929361A1
(de)
*
|
1999-06-25 |
2001-01-04 |
Basf Ag |
Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
|
ATE329579T1
(de)
|
1999-11-12 |
2006-07-15 |
Abbott Lab |
Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
|
DE10000792A1
(de)
*
|
2000-01-11 |
2001-07-19 |
Bernhard C Lippold |
Formulierungen von Wirkstoffen in Form einer festen Dispersion
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
DE60233874D1
(de)
|
2001-06-22 |
2009-11-12 |
Pfizer Prod Inc |
Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
|
TNSN03137A1
(en)
|
2001-06-22 |
2005-12-23 |
Pfizer Prod Inc |
PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
|
CA2474838C
(en)
*
|
2002-02-01 |
2009-01-06 |
Pfizer Products Inc. |
Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
|
MY140561A
(en)
*
|
2002-02-20 |
2009-12-31 |
Nycomed Gmbh |
Dosage form containing pde 4 inhibitor as active ingredient
|
GB0205253D0
(en)
*
|
2002-03-06 |
2002-04-17 |
Univ Gent |
Immediate release pharmaceutical granule compositions and a continuous process for making them
|
JP2005526083A
(ja)
*
|
2002-03-14 |
2005-09-02 |
ワトソン ファーマシューティカルズ, インコーポレイテッド |
プロゲステロンの経口薬物送達システム
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
US20050181032A1
(en)
*
|
2002-06-25 |
2005-08-18 |
Acrux Dds Pty Ltd. |
Metastable pharmaceutical compositions
|
NZ537360A
(en)
*
|
2002-06-25 |
2006-09-29 |
Acrux Dds Pty Ltd |
Transdermal delivery rate control using amorphous pharmaceutical compositions
|
WO2004069180A2
(en)
|
2003-01-31 |
2004-08-19 |
Smithkline Beecham Corporation |
Solid dispersion compositions
|
BRPI0407181A
(pt)
*
|
2003-02-03 |
2006-02-07 |
Novartis Ag |
Formulação farmacêutica
|
KR101179012B1
(ko)
|
2003-03-10 |
2012-09-03 |
니코메드 게엠베하 |
로플루미라스트 신규한 제조 방법
|
US20060182808A1
(en)
*
|
2003-04-29 |
2006-08-17 |
Akzo Nobel N.V. |
Antisolvent solidification process
|
CL2004000983A1
(es)
*
|
2003-05-08 |
2005-03-04 |
Altana Pharma Ag |
Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
|
PE20050150A1
(es)
*
|
2003-05-08 |
2005-03-22 |
Altana Pharma Ag |
Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
|
GB0315012D0
(en)
*
|
2003-06-27 |
2003-07-30 |
Leuven K U Res & Dev |
Zeotiles
|
US8273371B2
(en)
|
2003-06-27 |
2012-09-25 |
Johan Adriaan Martens |
Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
|
WO2005011635A2
(en)
|
2003-08-04 |
2005-02-10 |
Pfizer Products Inc. |
Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
CA2540984C
(en)
|
2003-10-10 |
2011-02-08 |
Lifecycle Pharma A/S |
A solid dosage form comprising a fibrate
|
PT1691787E
(pt)
*
|
2003-12-04 |
2008-09-02 |
Pfizer Prod Inc |
Método de formação de multipartículas farmacêuticas
|
KR100629771B1
(ko)
*
|
2004-01-27 |
2006-09-28 |
씨제이 주식회사 |
결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
|
US20050202079A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Mylan Pharmaceuticals Inc. |
Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
GB2418854B
(en)
*
|
2004-08-31 |
2009-12-23 |
Euro Celtique Sa |
Multiparticulates
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
AU2006224619B2
(en)
*
|
2005-03-16 |
2012-06-07 |
Takeda Gmbh |
Taste masked dosage form containing roflumilast
|
KR100627687B1
(ko)
*
|
2005-04-20 |
2006-09-25 |
주식회사 씨티씨바이오 |
시부트라민 유리염기 함유 조성물 및 이의 제조방법
|
WO2006112649A1
(en)
*
|
2005-04-20 |
2006-10-26 |
Ctc Bio, Inc. |
Pharmaceutical composition containing sibutramine free base and manufacturing method thereof
|
DE102005023803A1
(de)
*
|
2005-05-19 |
2006-11-23 |
Basf Ag |
Verfahren zur Herstellung von festen Blends aus Polyvinylpyrrolidonen und ethoxilierten Fettsäurederivaten
|
KR20070025070A
(ko)
*
|
2005-08-31 |
2007-03-08 |
주식회사 대웅제약 |
시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
|
GB0612695D0
(en)
*
|
2006-06-27 |
2006-08-09 |
Univ Gent |
Process for preparing a solid dosage form
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
US20080132560A1
(en)
*
|
2006-11-21 |
2008-06-05 |
San-Laung Chow |
Solid dispersion composition
|
WO2008079629A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Boehringer Ingelheim International Gmbh |
Formulations with improved bioavailability
|
KR20100134557A
(ko)
*
|
2008-01-11 |
2010-12-23 |
씨아이피엘에이 엘티디. |
고체 약제학적 투여 제형
|
US8383152B2
(en)
|
2008-01-25 |
2013-02-26 |
Gruenenthal Gmbh |
Pharmaceutical dosage form
|
HUE030803T2
(en)
|
2008-05-09 |
2017-06-28 |
Gruenenthal Gmbh |
Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spraying step \ t
|
AR077420A1
(es)
|
2009-07-22 |
2011-08-24 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion
|
EP2456427B1
(en)
|
2009-07-22 |
2015-03-04 |
Grünenthal GmbH |
Hot-melt extruded controlled release dosage form
|
MX346660B
(es)
*
|
2009-10-27 |
2017-03-28 |
Lupin Ltd |
Dispersion solida de rifaximina.
|
JP5933553B2
(ja)
|
2010-09-02 |
2016-06-15 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
アニオン性ポリマーを含む不正使用抵抗性剤形
|
ES2486791T3
(es)
|
2010-09-02 |
2014-08-19 |
Grünenthal GmbH |
Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
|
ES2571735T3
(es)
|
2010-10-20 |
2016-05-26 |
Dsm Ip Assets Bv |
Composiciones biodegradables que soportan grupo hidrófilo colgante y dispositivos relacionados
|
KR20180059560A
(ko)
*
|
2010-10-29 |
2018-06-04 |
애브비 인코포레이티드 |
아폽토시스―유도제를 포함하는 고체 분산체
|
RS56527B1
(sr)
|
2011-07-29 |
2018-02-28 |
Gruenenthal Gmbh |
Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
|
LT2736495T
(lt)
|
2011-07-29 |
2017-11-10 |
Grünenthal GmbH |
Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
|
WO2013030789A1
(en)
|
2011-08-30 |
2013-03-07 |
Ranbaxy Laboratories Limited |
Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
|
CA2864949A1
(en)
|
2012-02-28 |
2013-09-06 |
Grunenthal Gmbh |
Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
|
EP2838512B1
(en)
|
2012-04-18 |
2018-08-22 |
Grünenthal GmbH |
Tamper resistant and dose-dumping resistant pharmaceutical dosage form
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
KR102191562B1
(ko)
*
|
2012-11-07 |
2020-12-15 |
에스케이바이오팜 주식회사 |
난용성 약물의 고체분산체 및 이의 제조방법
|
JP6466417B2
(ja)
|
2013-05-29 |
2019-02-06 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
二峰性放出プロファイルを有する改変防止(tamper−resistant)剤形
|
MX371432B
(es)
|
2013-05-29 |
2020-01-30 |
Gruenenthal Gmbh |
Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
|
MX368846B
(es)
|
2013-07-12 |
2019-10-18 |
Gruenenthal Gmbh |
Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
|
WO2015071841A1
(en)
|
2013-11-12 |
2015-05-21 |
Druggability Technologies Holdings Limited |
Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
|
EP3073994A1
(en)
|
2013-11-26 |
2016-10-05 |
Grünenthal GmbH |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
EP3142646A1
(en)
|
2014-05-12 |
2017-03-22 |
Grünenthal GmbH |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
AU2015266117A1
(en)
|
2014-05-26 |
2016-11-24 |
Grunenthal Gmbh |
Multiparticles safeguarded against ethanolic dose-dumping
|
WO2016089796A1
(en)
*
|
2014-12-04 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Formulation inhibiting effects of low acid environment
|
EA035434B1
(ru)
|
2015-04-24 |
2020-06-15 |
Грюненталь Гмбх |
Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
|
JP2018526414A
(ja)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
|
CN113616599B
(zh)
*
|
2021-09-10 |
2022-11-18 |
宁夏医科大学 |
一种大黄素固体分散体及其制备方法与应用
|